high mobility group box 3 pseudogene 19Genealiases: []
Q-omics provides the consensus-scored HMGB3P19 profile across patient tissues and cancer cell-line models. HMGB3P19 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, HMGB3P19 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, HMGB3P19 RNA expression shows 6,135 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, LUAD, and STAD as cancer lineages where HMGB3P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P19 survival associations across molecular data types. HMGB3P19 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P19 RNA expression–survival associations across cancer types. High HMGB3P19 expression shows unfavorable associations in CESC, BLCA, SARC and BRCA, but favorable associations in KIRP and STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for HMGB3P19 RNA expression.
This table summarizes HMGB3P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P19 shows higher tumor expression in LUAD. The LUAD box plot shows higher HMGB3P19 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .049).
This table shows molecular features associated with HMGB3P19 in patient tissues and cancer cell lines. In patient samples, HMGB3P19 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
